While some analysts aren’t thrilled by Allergan's phase 2 data for Botox in depression, the company sees enough promise to move the therapy into a wide…

Mylan faces a class action lawsuit over its pricing of allergy shot EpiPen—the first suit alleging the company violated the federal RICO Act.

A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.

The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.

Hot on the heels of Tesaro's FDA nod for Zejula in ovarian cancer, AstraZeneca has nabbed priority review for its med Lynparza in the same treatment…

After a failed serelaxin trial, Novartis has to tear up sales estimates it hinted at in January, leaving Entresto to carry the load in heart failure—if it can…

Pfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with to target a rare, aggressive form of skin cancer.

U.S. government watchdogs plan to probe the FDA's orphan drug policies after Marathon's high-profile pricing scandal.

Regulatory